## **Core Concept**
Crohn's disease is a type of inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. Biological therapies, also known as biologics, are a class of medications that target specific proteins involved in the inflammatory process. They have become a cornerstone in the management of moderate to severe Crohn's disease.

## **Why the Correct Answer is Right**
The correct answer, **Infliximab**, is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), a key cytokine involved in the inflammatory cascade of Crohn's disease. By binding to TNF-α, infliximab reduces inflammation and prevents further tissue damage. Infliximab has been shown to induce and maintain clinical remission in patients with Crohn's disease and is considered an established biological therapy for this condition.

## **Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because, although it might represent another biologic agent, it is not the established therapy being referred to here.
* **Option B:** This option is incorrect for similar reasons; it could represent another therapeutic agent but is not infliximab.
* **Option D:** This option is incorrect as it does not correspond to infliximab.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that biologics like **infliximab** can increase the risk of infections and certain malignancies due to their immunosuppressive effects. Monitoring for these side effects is crucial during treatment.

## **Correct Answer:** . Infliximab